In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:

• How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? 
• Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?
• How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?
• How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?

Presenter:

Frederick L. Locke, MD
Co-Leader
Moffitt Immuno-Oncology Program
Vice Chair and Associate Member 
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director and Medical Director
Immune Cell Therapy Program
Moffitt Cancer Center
Tampa, Florida

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.

Link to full program: 
https://bit.ly/3rDeFCV

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.